New Data Demonstrating Long-term Benefits of FIRMAGON® (degarelix) for Advanced Hormone-dependant Prostate Cancer Published in The Journal of Urology

31.08.2011 – 08:02

2011 (ots/PRNewswire)

[Missing Content]

Contact:

Media enquiries: Orla Barnewell, Tonic Life Communications, Tel:
+44 207 798 9915, orla.barnewell@toniclc.com; Helen Swift, Tonic Life
Communications, Tel: +44 207 798 9924, helen.swift@toniclc.com;
Patrick
Gorman, Ferring Pharmaceuticals, Tel: +41 (0) 58 301 00 53
patrick.gorman@ferring.com

Weitere Storys: Ferring International SA

21.12.2009 – 10:47
Firmagon® has a significantly greater probability of PSA recurrence-free survival than Leuprolide in prostate cancer patients
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...
mehr
30.06.2009 – 10:07
New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
Amsterdam, The Netherlands (ots/PRNewswire) - - "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment" New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in ...
mehr
19.02.2009 – 15:55
European Commisssion grants Ferring Pharmaceuticals approval of FIRMAGON® (degarelix) for treatment of prostate cancer
New gonadotrophin-releasing hormone (GnRH) receptor antagonist demonstrates rapid, long-term suppression of testosterone Saint-Prex (ots) - Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON® (degarelix), a new GnRH receptor antagonist ...
mehr

Cookie Einstellungen